ジャパンタイムズ14h
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...
Chinese biotech dominance in R&D is on the rise
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
The Financial Express21h
Africa reports over 200 disease outbreaks in 2024; Cholera tops list
Health emergencies are on the rise in Africa. Last year, there were 213 public health outbreaks that the pan-African public ...
Hosted on MSN22h
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...